Abstract:

Recently, double-hit lymphoma (DHL) was clarified to be a molecular category of B-cell lymphoma, which was mainly related to MYC and Bcl-2 genes translocation. Fluorescence in situ hybridization (FISH) is the gold standard of diagnosis and it is controversial to detect the expression of MYC and Bcl-2 protein by immunohistochemistry. DHL, which was found to be aggressive according to many retrospective analyses, mainly develops in patients with diffuse large B-cell lymphoma and grey zone lymphoma. Both rituximab combination and transplant consolidation were not able to significantly overcome the poor prognosis of DHL. Novel and specific molecular targeted agents need to be explored and investigated in order to improve the treatment outcome.

Key words: Double-hit lymphoma, Diagnosis, Treatment, Prognosis